Amplification of the response to toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: Implication for the pathogenesis of macrophage activation syndrome

Arthritis and Rheumatism

Volumn 64, Issue 5, 2012, Pages 1680-1688

  Strippoli, Raffaele ^a   Carvello, Francesco ^a   Scianaro, Roberta ^a   De Pasquale, Loredana ^a   Vivarelli, Marina ^a   Petrini, Stefania ^a   Bracci Laudiero, Luisa ^b   De Benedetti, Fabrizio ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEMOGLOBIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STAT3 PROTEIN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD CELL COUNT; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FATALITY; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MACROPHAGE ACTIVATION SYNDROME; MONONUCLEAR CELL; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PATHOGENESIS; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPLEEN CELL; SURVIVAL RATE; THROMBOCYTE COUNT; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL MARKERS; CYTOKINES; DISEASE MODELS, ANIMAL; HEMATOLOGIC TESTS; HUMANS; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LIGANDS; LIPOPOLYSACCHARIDES; LONGEVITY; MACROPHAGE ACTIVATION SYNDROME; MACROPHAGES, PERITONEAL; MICE; MICE, TRANSGENIC; SPLEEN; TOLL-LIKE RECEPTORS;

EID: 84860458850     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33496     Document Type: Article

References (47)

1. Nishimoto N, Kishimoto T,. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006; 2: 619-26.
2. Naugler WE, Karin M,. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14: 109-19.
3. Fonseca JE, Santos MJ, Canhao H, Choy E,. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009; 8: 538-42.
4. Chai Z, Gatti S, Toniatti C, Poli V, Bartfai T,. Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1β: a study on IL-6-deficient mice. J Exp Med 1996; 183: 311-6.
5. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994; 180: 1243-50.
6. De Benedetti F, Martini A,. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? [editorial]. Arthritis Rheum 2005; 52: 687-93.
7. Mima T, Nishimoto N,. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol 2009; 21: 224-30.
8. De Benedetti F, Brunner H, Ruperto N, Calvo I, Cuttica R, Malattia C, et al. Tocilizumab in patients with systemic juvenile idiopathic arthritis: efficacy data from the placebo-controlled 12-week part of the Phase 3 TENDER Trial [abstract]. Arthritis Rheum 2010; 62 Suppl: S596.
9. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F,. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374: 1-20.
10. Takeuchi O, Akira S,. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-20.
11. Lu YC, Yeh WC, Ohashi PS,. LPS/TLR4 signal transduction pathway. Cytokine 2008; 42: 145-51.
12. Ravelli A,. Macrophage activation syndrome. Curr Opin Rheumatol 2002; 14: 548-52.
13. Grom AA, Mellins ED,. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol 2010; 22: 561-6.
14. Grom AA,. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr Opin Rheumatol 2003; 15: 587-90.
15. Kelly A, Ramanan AV,. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol 2007; 19: 477-81.
16. Maruyama J, Inokuma S,. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol 2010; 37: 967-73.
17. Vastert SJ, van Wijk R, D'Urbano LE, de Vooght K, de Jager W, Ravelli A, et al. Mutations in the perforin gene may be linked to macrophage activation syndrome in patients with systemic-onset juvenile idiopathic arthritis. Rhematology (Oxford) 2010; 49: 441-9.
18. Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum 2008; 58: 2892-6.
19. Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier; 2011.
20. De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I: a model for stunted growth in children with chronic inflammation. J Clin Invest 1997; 99: 643-50.
21. De Benedetti F, Rucci N, Del Fattore A, Peruzzi B, Paro R, Longo M, et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006; 54: 3551-63.
22. Martinez FO, Gordon S, Locati M, Mantovani A,. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006; 177: 7303-11.
23. Hamilton JA,. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8: 533-44.
24. Wierenga AT, Vogelzang I, Eggen BJ, Vellenga E,. Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway. Exp Hematol 2003; 31: 398-405.
25. Guha M, Mackman N,. LPS induction of gene expression in human monocytes. Cell Signal 2001; 13: 85-94.
26. Guha M, O'Connell MA, Pawlinski R, Hollis A, McGovern P, Yan SF, et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor α expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 2001; 98: 1429-39.
27. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998; 101: 311-20.
28. Di Santo E, Alonzi T, Poli V, Fattori E, Toniatti C, Sironi M, et al. Differential effects of IL-6 on systemic and central production of TNF: a study with IL-6-deficient mice. Cytokine 1997; 9: 300-6.
29. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998; 187: 461-8.
30. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, et al. Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 2004; 114: 582-8.
31. Nishimoto N,. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther 2010; 87: 483-7.
32. Greenhill CJ, Rose-John S, Lissilaa R, Ferlin W, Ernst M, Hertzog PJ, et al. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol 2011; 186: 1199-208.
33. Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophages. Blood 2009; 113: 2324-35.
34. Sun W, Snyder M, Levy DE, Zhang JJ,. Regulation of Stat3 transcriptional activity by the conserved LPMSP motif for OSM and IL-6 signaling. FEBS Lett 2006; 580: 5880-4.
35. Yoshida Y, Kumar A, Koyama Y, Peng H, Arman A, Boch JA, et al. Interleukin 1 activates STAT3/nuclear factor-κB cross-talk via a unique TRAF6- and p65-dependent mechanism. J Biol Chem 2004; 279: 1768-76.
36. Guo HF, Liu SX, Zhang YJ, Liu QJ, Hao J, Gao LX,. High mobility group box 1 induces synoviocyte proliferation in rheumatoid arthritis by activating the signal transducer and activator transcription signal pathway. Clin Exp Med 2011; 11: 65-74.
37. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J Exp Med 2002; 195: 99-111.
38. Roelofs MF, Boelens WC, Joosten LA, Abdollahi-Roodsaz S, Geurts J, Wunderink LU, et al. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J Immunol 2006; 176: 7021-7.
39. Huang QQ, Pope RM,. The role of Toll-like receptors in rheumatoid arthritis. Curr Rheumatol Rep 2009; 11: 357-64.
40. Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest 2011; 121: 2264-77.
41. Davi S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2011; 38: 764-8.
42. Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005; 146: 598-604.
43. Jordan MB, Hildeman D, Kappler J, Marrack P,. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon γ are essential for the disorder. Blood 2004; 104: 735-43.
44. Crozat K, Hoebe K, Ugolini S, Hong NA, Janssen E, Rutschmann S, et al. Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis [published erratum appears in J Exp Med 2008;205:737]. J Exp Med 2007; 204: 853-63.
45. Pachlopnik Schmid J, Ho CH, Chretien F, Lefebvre JM, Pivert G, Kosco-Vilbois M, et al. Neutralization of IFNγ defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med 2009; 1: 112-24.
46. Yanagimachi M, Naruto T, Miyamae T, Hara T, Kikuchi M, Hara R, et al. Association of IRF5 polymorphisms with susceptibility to macrophage activation syndrome in patients with juvenile idiopathic arthritis. J Rheumatol 2011; 38: 769-74.
47. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ,. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 2011; 50: 417-9.